| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $22,924,468 | 2 | 17 |
Sells | $10,109,670 | 10 | 83 |
| WALTERS GROUP | 10 percent owner | 2 | $22.92M | 0 | $0 | $22.92M |
| Bruns Ingmar | Chief Medical Officer | 0 | $0 | 2 | $7,998 | $-7,998 |
| EASTLAND JULIA MARIE | CEO & President | 0 | $0 | 2 | $21,239 | $-21,239 |
| Vultaggio Vincent | PAO and PFO | 0 | $0 | 5 | $105,432 | $-105,432 |
| Matrix Capital Management Company, LP | 10 percent owner | 0 | $0 | 1 | $9.97M | $-9.97M |
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Over the last 12 months, insiders at Zentalis Pharmaceuticals, Inc. have bought $22.92M and sold $10.11M worth of Zentalis Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Zentalis Pharmaceuticals, Inc. have bought $32.81M and sold $7.71M worth of stock each year.
Highest buying activity among insiders over the last 12 months: WALTERS GROUP (10 percent owner) — $22.92M.
The last purchase of 4,335,000 shares for transaction amount of $15.17M was made by WALTERS GROUP (10 percent owner) on 2026‑08‑14.
| 2026-08-14 | WALTERS GROUP | 10 percent owner | 4.33M 6.0656% | $3.50 | $15.17M | -22.05% | ||
| 2026-02-10 | Sale | Vultaggio Vincent | PAO and PFO | 6,894 0.0096% | $2.42 | $16,699 | +54.38% | |
| 2026-02-09 | Sale | Vultaggio Vincent | PAO and PFO | 3,379 0.0047% | $2.39 | $8,086 | +54.17% | |
| 2026-02-09 | Sale | EASTLAND JULIA MARIE | CEO & President | 889 0.0012% | $2.39 | $2,127 | +54.17% | |
| 2026-02-09 | Sale | Bruns Ingmar | Chief Medical Officer | 335 0.0005% | $2.39 | $802 | +54.17% | |
| 2026-02-06 | Sale | Vultaggio Vincent | PAO and PFO | 29,951 0.0421% | $2.43 | $72,772 | +54.39% | |
| 2026-02-06 | Sale | EASTLAND JULIA MARIE | CEO & President | 7,866 0.0111% | $2.43 | $19,112 | +54.39% | |
| 2026-02-06 | Sale | Bruns Ingmar | Chief Medical Officer | 2,962 0.0042% | $2.43 | $7,197 | +54.39% | |
| 2026-02-03 | Sale | Vultaggio Vincent | PAO and PFO | 556 0.0007% | $2.52 | $1,398 | +30.50% | |
| 2026-02-02 | Sale | Vultaggio Vincent | PAO and PFO | 2,540 0.0036% | $2.55 | $6,477 | +46.41% | |
| 2025-12-31 | WALTERS GROUP | 10 percent owner | 6.46M 8.0671% | $1.20 | $7.75M | +162.22% | ||
| 2025-12-15 | Sale | Matrix Capital Management Company, LP | 10 percent owner | 7.5M 9.8968% | $1.33 | $9.97M | +149.64% | |
| 2025-04-30 | Myers Scott Dunseth | director | 21,000 0.0288% | $1.40 | $29,373 | +6.34% | ||
| 2025-02-06 | Bruns Ingmar | Chief Medical Officer | 20,000 0.0299% | $2.28 | $45,656 | -31.94% | ||
| 2025-02-03 | Sale | Paul Andrea | Chief Legal Officer | 13,230 0.0183% | $1.71 | $22,643 | -12.50% | |
| 2025-02-03 | Sale | Lackner Mark | Chief Scientific Officer | 14,368 0.0198% | $1.71 | $24,591 | -12.50% | |
| 2025-02-03 | Sale | Vultaggio Vincent | PAO and Interim PFO | 2,615 0.0036% | $1.71 | $4,476 | -12.50% | |
| 2025-01-31 | Skvarka Jan | director | 60,000 0.0874% | $1.72 | $103,446 | -15.80% | ||
| 2025-01-31 | Walker Luke Nathaniel | director | 14,200 0.0211% | $1.76 | $24,966 | -15.80% | ||
| 2025-01-31 | EASTLAND JULIA MARIE | CEO & President | 28,500 0.0417% | $1.73 | $49,345 | -15.80% |
| WALTERS GROUP | 10 percent owner | 17844973 25.068% | $31.76M | 2 | 0 | |
| Matrix Capital Management Company, LP | 10 percent owner | 6459973 9.0747% | $11.5M | 1 | 1 | <0.0001% |
| EASTLAND JULIA MARIE | CEO & President | 79133 0.1112% | $140,856.74 | 1 | 2 | <0.0001% |
| Bruns Ingmar | Chief Medical Officer | 33332 0.0468% | $59,330.96 | 1 | 2 | <0.0001% |
| VIKING GLOBAL INVESTORS LP | 10 percent owner | 3943284 5.5394% | $7.02M | 1 | 1 | +70.78% |
| SUN ANTHONY Y | President & CEO | 1175589 1.6514% | $2.09M | 1 | 30 | +70.78% |
| Bunker Kevin D. | Chief Scientific Officer | 859089 1.2068% | $1.53M | 1 | 41 | +70.78% |
| Epperly Melissa B, | Chief Financial Officer | 451449 0.6342% | $803,579.22 | 3 | 18 | +21.94% |
| Myers Scott Dunseth | director | 281192 0.395% | $500,521.76 | 1 | 0 | +6.34% |
| Blackwell Kimberly | Chief Executive Officer | 254800 0.3579% | $453,544.00 | 1 | 4 | +9.75% |
| Skvarka Jan | director | 149551 0.2101% | $266,200.78 | 1 | 1 | <0.0001% |
| Johnson David Michael | director | 144389 0.2028% | $257,012.42 | 2 | 3 | +42.68% |
| Walker Luke Nathaniel | director | 86681 0.1218% | $154,292.18 | 1 | 0 | <0.0001% |
$16,280,851 | 76 | 1.48% | $118.27M | |
$4,898,715 | 46 | 40.75% | $114.69M | |
$6,788,859 | 35 | 26.72% | $151.54M | |
$7,147,964 | 34 | 24.77% | $166.39M | |
$47,438,336 | 33 | -21.38% | $122.37M |
| Increased Positions | 36 | +29.75% | 9M | +17.66% |
| Decreased Positions | 51 | -42.15% | 21M | -40.3% |
| New Positions | 8 | New | 2M | New |
| Sold Out Positions | 18 | Sold Out | 17M | Sold Out |
| Total Postitions | 106 | -12.4% | 41M | -22.64% |
| Matrix Capital Management Company, Lp | $19,125.00 | 19.39% | 13.96M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $3,979.00 | 4.03% | 2.9M | +19,768 | +0.69% | 2025-09-30 |
| Acadian Asset Management Llc | $3,898.00 | 3.95% | 2.85M | +46,132 | +1.65% | 2025-09-30 |
| Renaissance Technologies Llc | $3,186.00 | 3.23% | 2.33M | +795,802 | +52.03% | 2025-09-30 |
| Citadel Advisors Llc | $2,846.00 | 2.89% | 2.08M | +2M | +349.3% | 2025-09-30 |
| Tang Capital Management Llc | $2,124.00 | 2.15% | 1.55M | 0 | 0% | 2025-09-30 |
| Bank Of America Corp /De/ | $2,122.00 | 2.15% | 1.55M | +835,466 | +117.12% | 2025-09-30 |
| Two Sigma Advisers, Lp | $2,002.00 | 2.03% | 1.46M | +185,286 | +14.52% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $1,930.00 | 1.96% | 1.41M | +211,179 | +17.63% | 2025-09-30 |
| Morgan Stanley | $1,929.00 | 1.96% | 1.41M | +310,178 | +28.26% | 2025-09-30 |